YOU STOPPED AT: Summary: Risk Classification vs. Prognosis The Key Distinction Concept Your Status Meaning Risk...

Your Risk Classification, PSA Nadir, and Long-Term Prognosis (Continued)

Summary: Risk Classification vs. Prognosis

The Key Distinction

| Concept | Your Status | Meaning | |---|---|---| | Risk Classification | Favorable Intermediate Risk | Based on Gleason 3+4=7 at diagnosis | | PSA Nadir | 0.004 ng/mL (Excellent) | Reflects complete cancer removal | | Prognosis | Excellent | 85-90% 5-year BCRFS | | Long-term Outcome | Very favorable | Prostate cancer unlikely to be life-limiting |

---

What This Means for Your Future

Your Prognosis is Excellent — Here's Why

You have achieved the optimal post-operative outcome:

1. ✅ Complete cancer removal (PSA nadir 0.004 ng/mL)
2. ✅ Organ-confined disease (pT2 — cancer didn't escape the prostate)
3. ✅ Intermediate-grade cancer (Gleason 3+4=7 — not high-grade)
4. ✅ Negative surgical margins (close margin, but not positive)
5. ✅ Stable PSA trajectory (no rising trend at 10 months)

Combined, these factors predict:

• 85-90% chance of remaining biochemical recurrence-free at 5 years
• 75-80% chance of remaining biochemical recurrence-free at 10 years
• Normal life expectancy (prostate cancer unlikely to be life-limiting)

Source: NCCN Guidelines for Prostate Cancer (2025) — Prognostic factors and long-term outcomes for favorable intermediate risk prostate cancer

---

Your Monitoring Plan Going Forward

What You Should Expect

According to NCCN Guidelines for Prostate Cancer (2025) and EAU Guidelines (2023):

PSA monitoring schedule for post-prostatectomy patients:

| Time Point | Recommended Frequency | Your Current Status | |---|---|---| | Months 0-6 | Every 4-6 weeks | ✅ Complete | | Months 6-12 | Every 3 months | ✅ Complete (at 10 months) | | Year 2 | Every 3-6 months | 📋 Upcoming | | Years 3-5 | Every 6-12 months | 📋 Upcoming | | Year 5+ | Annually | 📋 Long-term |

Your next steps:

• Continue PSA monitoring every 3-6 months through year 2
• Transition to every 6-12 months in years 3-5
• Annual PSA testing after year 5

What to watch for:

• ✅ PSA remains undetectable (<0.1 ng/mL)
• ⚠️ PSA rises above 0.1 ng/mL (biochemical recurrence)
• ⚠️ PSA doubling time <3 months (aggressive recurrence)

Source: NCCN Guidelines for Prostate Cancer (2025) — Post-operative surveillance for prostate cancer

---

Biochemical Recurrence: What It Means and What to Do

If PSA Rises (Biochemical Recurrence)

Important: Biochemical recurrence (BCR) is NOT the same as cancer recurrence. It's an early warning sign that requires further evaluation.

Definition of BCR:

• PSA rises above 0.1 ng/mL after being undetectable, OR
• PSA rises on two consecutive tests

If this happens:

1. Confirm the rise with repeat PSA testing
2. Assess PSA doubling time (how fast PSA is rising)
3. Imaging studies (PSMA-PET scan or other imaging)
4. Salvage therapy options if cancer is localized:
   • Salvage radiation therapy (most common)
   • Salvage hormone therapy
   • Clinical trials

Important: BCR does NOT mean your cancer has returned to your body. It means PSA is detectable again, which requires further investigation.

Your risk: 10-15% chance of BCR in years 1-5 (favorable intermediate risk)

Source: NCCN Guidelines for Prostate Cancer (2025) — Management of biochemical recurrence after prostatectomy

---

Key Questions to Ask Your Oncologist

To Ensure Optimal Long-Term Monitoring

1. "What PSA level should trigger further investigation?"

   • Standard answer: PSA >0.1 ng/mL or rising on consecutive tests

2. "How often should I have PSA testing?"

   • Your answer: Every 3-6 months through year 2, then every 6-12 months

3. "What imaging would you recommend if my PSA rises?"

   • Standard answer: PSMA-PET scan (most sensitive for detecting recurrence)

4. "What are my salvage therapy options if BCR occurs?"

   • Standard answer: Salvage radiation therapy (if cancer is localized)

5. "What is my estimated 5-year and 10-year recurrence-free survival?"

   • Your answer: 85-90% at 5 years, 75-80% at 10 years

6. "Are there any lifestyle factors that might reduce my recurrence risk?"

   • Standard answer: Healthy diet, exercise, weight management, smoking cessation

Source: NCCN Guidelines for Prostate Cancer (2025) — Patient education and shared decision-making

---

Final Clinical Summary

Your Current Status: 10 Months Post-Prostatectomy

| Assessment | Finding | Clinical Significance | |---|---|---| | Cancer removal | Complete (PSA 0.004 ng/mL) | ✅ Excellent | | Surgical margins | Close, not positive | ✅ Favorable | | Pathological stage | pT2 (organ-confined) | ✅ Favorable | | Gleason score | 3+4=7 (Grade Group 2) | ⚠️ Intermediate | | Risk classification | Favorable Intermediate Risk | ✅ Good prognosis | | 5-year BCRFS | 85-90% | ✅ Excellent | | 10-year BCRFS | 75-80% | ✅ Excellent | | Life expectancy | Normal | ✅ Prostate cancer unlikely to be life-limiting |

---

Bottom Line

You have achieved an excellent post-operative outcome with:

• ✅ Complete cancer removal
• ✅ Excellent PSA nadir
• ✅ Favorable intermediate risk classification
• ✅ 85-90% chance of remaining cancer-free at 5 years
• ✅ Normal life expectancy

Your prognosis is excellent. Continue regular PSA monitoring and maintain healthy lifestyle habits. Your surgeon successfully removed your cancer, and your current trajectory suggests long-term cancer control.

---

Important Reminders

Supportive Care and Quality of Life

According to NCCN Guidelines for Prostate Cancer (2025), post-prostatectomy patients should address:

Physical health:

• ✅ Pelvic floor exercises (for urinary continence)
• ✅ Sexual rehabilitation (for erectile function)
• ✅ Regular exercise and healthy diet
• ✅ Weight management

Mental health:

• ✅ Counseling if experiencing anxiety or depression
• ✅ Support groups for prostate cancer survivors
• ✅ Open communication with your care team

Follow-up care:

• ✅ Regular PSA monitoring
• ✅ Annual digital rectal exams (if recommended)
• ✅ Imaging if PSA rises
• ✅ Salvage therapy if needed

Source: NCCN Guidelines for Prostate Cancer (2025) —